Bell

Evolution of virus

1	
2	
3	
4	
5	
6	Evolutionary dynamics of a virus in a vaccinated population
7	Graham Bell
8	
9	
10	Biology Department and Redpath Museum
11	McGill University
12	Montreal, Quebec H3A 1B1, Canada
13	
14	Email: graham.bell@mcgill.ca
15	

Evolution of virus

16 <u>Summary</u>

17	The progress of an epidemic in a small closed community is simulated by an agent-based model
18	which allows vaccination and variation. The attributes of the virus are governed by two genetic
19	loci: the P-locus, which determines growth, and the M-locus, which determines immune
20	characteristics. Mutation at either locus modifies the attributes of the virus and leads to
21	evolution through natural selection. For both loci the crucial variable is the potential mutation
22	supply U_{Pot} , because evolution is likely to happen when $U_{Pot} > 1$. Mutation at the P-locus causes
23	a limited increase in virulence, which may be affected by vaccine design. Mutation at the M-
24	locus may cause a qualitative shift of dynamic regime from a simple limited epidemic to a
25	perennial endemic disease by giving rise to escape mutants which may themselves mutate. A
26	broad vaccine that remains efficacious despite several mutations at the M-locus prevents this
27	shift and provides protection despite the evolution of the virus. Escape variants may
28	nevertheless arise through recombination after coinfection, and can be suppressed by timely
29	revaccination, using the prevalent strain to design the vaccine.

Evolution of virus

Bell

31

2	2
.3	2
-	_

Introduction

33	Once a virus has first infected a single individual in a population of susceptible hosts, its lineage
34	may subsequently follow one of two paths: either it fails to be transmitted and soon becomes
35	extinct, or it proliferates so as to cause an epidemic. Which path is followed depends in part on
36	deterministic factors, such as its initial rate of transmission, and in part on stochastic factors,
37	because the initial survival and transmission of the virus are strongly influenced by chance. The
38	time course of an epidemic in a local population can be adequately described by the
39	mathematical theory that has been developed over the last century (reviewed by Brauer 2017).
40	If the virus is liable to vary when it replicates, however, the virus population will evolve during
41	the epidemic and as its properties change its dynamics may become more complicated (Lenski
42	& May 1994, Day & Proulx 2004, Day & Gandon 2007), as in the well-known case of influenza
43	(reviewed by Nelson & Holmes 2007). As for the virus population as a whole, the spread of any
44	new strain, beginning with a single individual arising by mutation or recombination, will be
45	influenced both by deterministic processes such as natural selection and by stochastic
46	processes such as genetic drift. The ongoing pandemic caused by the coronavirus SARS-CoV-2
47	has made the public more aware of virus evolution and more fearful of its consequences, as the
48	spread of new strains undermines efforts to control the outbreak (Day et al. 2021).
49	Novel mutations which arise during the proliferation of an ancestral strain may modify the
50	propensity to infect naïve hosts, which have never before been infected by the ancestor, or the
51	ability to infect recovered hosts, which have previously been infected but then cleared the

Evolution of virus

Bell

52	virus. The first kind, often called virulence or life-history variants, alters the extent of
53	proliferation within the host, which results in a viral titre characteristic of a particular strain.
54	This in turn affects its virulence, because a higher titre causes more severe symptoms and
55	endangers the host, and its transmissibility, because a higher titre results in more virus particles
56	being shed (May & Anderson 1983, van Baalen & Sabelis 1995). The second kind, often called
57	escape variants, alters the antigenic properties of the virus and may thereby enable it to evade
58	the immune system of the host (Gog & Grenfell 2002, Grenfell et al. 2004, Fryer & McLean
59	2011). These two approaches use different methods and have remained largely separate. The
60	evolution of virulence is usually viewed as a long-term process using quantitative population
61	genetics to model competition between many virus lineages, whereas escape is usually
62	represented as the short-term outcome of competition between two clones of virus (Gandon &
63	Day 2007).

64 Vaccination protects the population by arming individuals with an immune response against virus strains which have an antigenic profile similar to the vaccine. It is an effective method of 65 reducing the incidence of the disease, and may even drive the virus extinct if the frequency of 66 67 unvaccinated hosts is too low to sustain an epidemic (Anderson & May 1991). It is also a profound alteration of the host environment, however, and may thereby act as an agent of 68 selection on the virus population. Moreover, vaccinated individuals are not necessarily 69 70 equivalent to recovered individuals, either in terms of their immune response or the virulence 71 and transmissibility of any infection which succeeds in taking hold. When there are many strains of virus circulating in a vaccinated population, each differing in its virulence, 72 73 transmissibility and antigenic properties, and each subject to stochastic as well as deterministic

Evolution of virus

Bell

74	change, then analytical solutions of conventional mathematical models based on differential
75	equations may be difficult to find (although Day et al. 2020 show how a complex situation can
76	be analysed). Numerical solutions can still be found, of course, but agent-based simulations
77	can be used instead (e.g. Roche, Drake & Rohani 2011). These can incorporate any number of
78	parameters with ease, at the expense of making it difficult to explore the parameter space
79	thoroughly and correspondingly difficult either to identify or to validate general principles. The
80	most radical approach is to abandon equations altogether, in favour of a set of rules that
81	govern how individuals move around, meet one another, and infect others or are themselves
82	infected. In this report I shall use an agent-based model based on rules rather than equations to
83	describe the evolutionary dynamics of a virus in a vaccinated population. The virus resembles
84	SARS-CoV-2 in some respects, but the model is intended only to suggest some general features
85	of virus evolution, rather than to predict the future course of the pandemic.
86	
87	Methods

This report is based on an agent-based, quasi-realistic model of an epidemic in an imaginary small town described in a previous report (Bell 2020). The program itself and a detailed account of the model are included in the Supplementary Material.

Variation and mutation. The virus has two loci that govern its interaction with a host. The
Phenotype or P-locus governs the proliferation of the virus within the host, and thereby its
virulence and transmissibility. The Immunity or M-locus governs the interaction of the virus
with the immune system of the host. The ancestral strain responsible for the outbreak has

Evolution of virus

Bell

given states at the P-locus and the M-locus that determine its transmissibility, virulence and
immune characteristics.

97 Each locus consists of a string of given length of binary digits ('bits'), one of which is switched from one state to the other when mutation occurs. Competition within the host is neglected, 98 99 for simplicity, so that only successful mutations are considered – those that both arise and become fixed within an infected host, which then transmits the mutant strain. The effect of a 100 mutation at the P-locus is to increase viral titre by a random factor from the value in the 101 102 ancestral strain towards some fixed maximal value, leading to an increase, by a different 103 random amount, in both transmissibility and virulence. A mutation at the M-locus alters the 104 antigenic properties of the virus and may thereby enable it to evade the immune system of the 105 host.

The number of mutations at either locus is limited by the number of times that the virus is 106 transmitted, which for the ancestral strain is at most equal to the size of the host population. 107 108 We can then define the potential mutation supply for either locus as U_{Pot} = HuL, where H is the number of individuals in the host population, u is the fundamental rate of mutation per site, 109 and L is the number of mutable sites at the locus. In an unvaccinated population, at least one 110 mutation will arise, on average, if $U_{Pot} > 1$. Mutation and the initial spread of a mutant strain 111 112 are stochastic events, however, so no mutation may occur, or, if it does, the new strain may soon become extinct. In a vaccinated population the condition is more stringent because a 113 114 successful mutant must arise before the host population is fully vaccinated.

Evolution of virus

Bell

115	Immune response. In response to infection by a strain of virus with a given epitope sequence at
116	its M-locus, the host generates an antibody with the complementary sequence and stores this
117	in its immune memory. (For example, if the virus M-locus is 001011001, the host generates and
118	stores 110100110.) If the host survives and is subsequently exposed to the same strain of virus,
119	it is able to express the stored sequence and may thereby disable the virus. The effectiveness
120	of the immune response depends on how the clearance of the virus is related to the degree of
121	complementarity. The simplest mechanism is always to activate the immune response if
122	complementarity equals or exceeds some threshold value, or alternatively the probability of
123	activation might decrease continuously as some function of decreasing complementarity.
124	Vaccination. In vaccinated hosts, the sequence complementary to the vaccine sequence is
125	likewise stored in immune memory. Vaccination is akin to previous infection by a virus whose
126	sequence at the M-locus corresponds to the vaccine. It will thereby confer some degree of
127	immunity to this strain of the virus: complete immunity for a highly efficacious vaccine, but only
128	partial immunity for a low-efficacy vaccine. If the host is exposed to a strain of virus whose M-
129	locus does not correspond exactly with the vaccine, its immunity will be less, to an extent that
130	depends on the specificity of the vaccine. A narrow vaccine will activate the immune response,
131	but only if it is fully complementary to an invading virus; a broad vaccine may be less effective
132	against a fully complementary virus, but might be active to some extent against a strain with
133	partial complementarity.

134 If an individual becomes infected by the virus despite vaccination or previous infection, the 135 virus population within the host will grow, as it does in naïve hosts. It may grow to a different 136 titre in naïve, recovered and vaccinated individuals, however, so that its virulence and

Evolution of virus

Bell

137	transmissibility will in general differ between these categories of host. A weak vaccine permits
138	a higher titre and thereby greater virulence and transmissibility, whereas a strong vaccine
139	suppresses the growth of the virus and reduces both virulence and transmissibility, relative to
140	naïve unvaccinated individuals.
141	Standard parameter set. The simulations reported here were conducted in a small town of
142	about 4000 people with a demographic and occupational profile similar to that of many
143	communities in Europe and North America. The parameters for the simulations reported here
144	were chosen so that an epidemic infects about 75 – 80% of an unvaccinated population over a
145	period of about 100 days before the virus is no longer able to propagate and becomes locally
146	extinct. The authorities may take measures to control, curtail or delay the epidemic, including
147	vaccination. A vaccination program proceeds as a specified series of cohorts identified by age
148	and occupation. In the simulations reported here, vaccination gives permanent protection and
149	all individuals are vaccinated during the program, regardless of infection history and current
150	status, although the model allows incomplete compliance and temporary immunity.
151	
152	Results and Discussion
153	
154	Weak and strong vaccines. The effects of mutation at the P-locus on virulence and
155	transmissibility are antagonistic, because hosts infected by a mutant strain with increased
156	virulence are more likely to die and thus unable to transmit the virus. The spread of a mutant

157 strain is therefore governed by the balance of positive and negative effects on the rate of

Evolution of virus

Bell

158	transmission, which is expected to lead to an optimal intermediate level of virulence (Anderson
159	& May 1982). This balance may be shifted by vaccination. In particular, the cost of virulence
160	arising from the excess death rate of infected hosts is reduced if the virus is able to grow slowly
161	in vaccinated hosts, so that selection will favour increased growth and hence increased
162	virulence. This possibility has led to the controversial conclusion that a weak vaccine may
163	actually favour the spread of more virulent strains of the virus (Gandon et al. 2001; Gandon et
164	al. 2003).

165 The simplest model is to suppose that naïve hosts are completely susceptible and recovered 166 hosts are completely immune, whereas vaccinated hosts have an intermediate level of 167 immunity. The virulence of the ancestral strain of virus in those vaccinated hosts which 168 become infected is likewise intermediate between its value in naive and recovered hosts. We 169 then expect that greater virulence will evolve in vaccinated hosts, and consequently that 170 virulence in naïve hosts will increase as a correlated response to selection. As mutations at the P-locus arise and spread by virtue of their increased transmissibility, the mean virulence of the 171 virus, over all infected hosts, will tend to increase. The maximum value of mean virulence 172 173 during the epidemic is shown in Figure 1 for replicate populations with different vaccination states. A weak vaccine does induce the evolution of somewhat greater virulence in naïve hosts, 174 175 relative to a strong vaccine, but the difference between weak and strong vaccines is not 176 formally significant (F = 3.4; df = 1, 38; 0.1 > P > 0.05), and virulence is greatest in unvaccinated populations because of their greater mutation supply. Selection for increased virulence is 177 178 expected to be slight, because individuals who die have already had the opportunity to transmit 179 the virus (Day et al. 2020). It is also highly variable because it depends on two stochastic

Evolution of virus

Bell

factors: the effect of mutations on virulence and transmissibility, and their timing relative to the 180 181 vaccination program. The incidence of cases with severe symptoms (which may result in death) is increased by mutation and reduced by vaccination, while the difference between weak and 182 strong vaccines is imperceptible (Supplementary Figure 1). 183 Evolution of antigenic evasion. Without variation at the M-locus, vaccination using the 184 ancestral strain as a model halts the epidemic and substantially reduces the number of cases, 185 provided that it is efficacious, universally administered and timely. Even if these conditions are 186 187 met, however, mutations at the M-locus may enable the virus to spread, provided they are 188 sufficiently frequent. If $U_{Pot} < 1$ it is unlikely (but not impossible) that any mutations will occur, and vaccination will be effective. If $U_{Pot} > 1$ then escape mutations will usually (although not 189 always) occur, and lineages bearing these mutations can spread even in a fully vaccinated 190 191 population because they render the whole population susceptible: mutations of this sort create 192 their own potential mutation supply, and may thereby give rise to an indefinite series of further mutations in the future. The succession of mutant strains can shift the population from one 193 dynamic regime to another (Supplementary Figure 2). In the first place, a mutant strain may 194 195 spread after the initial collapse of the epidemic, which will follow from vaccination or simply from the reduced availability of hosts who are susceptible to the ancestral strain. As the 196 mutant strain in turn declines in abundance it can be replaced by a third mutant strain, if one 197 198 should occur, and in this way give rise to a more or less regular succession of disease cycles. Alternatively, if $U_{Pot} >> 1$ mutant strains might arise so frequently that several will be circulating 199 at any given time, and the virus might be maintained for a long period of time with irregular 200 201 low-amplitude fluctuations over time, before eventually becoming stochastically extinct. Figure

Evolution of virus

Bell

202	2 shows that the shift from a short-term regular epidemic to a longer-term evolving epidemic in
203	a vaccinated population occurs around the critical potential mutation supply of $U_{Pot} \approx 1$. The
204	shift from one dynamic regime to another is thus governed by the potential mutation supply.
205	No such shift will occur in an unvaccinated population, because escape mutations will spread
206	only in recovered individuals. Most of these will appear relatively early in the epidemic
207	(because the rate of transmission and thus the opportunity for mutation is greatest at this
208	time), before many host individuals have recovered from the infection and are immune to the
209	ancestral strain. Consequently, the density of susceptible hosts is not much greater for a
210	mutant and its selective advantage is only modest, so the lineage will spread only slowly and is
211	likely to die out. In a vaccinated population, on the other hand, the transmission of the
212	ancestral strain is blocked by the vaccine, the selective advantage of mutants is correspondingly
213	much greater, and a mutant lineage can rapidly expand to fill the ecological space provided by
214	vaccinated but susceptible hosts. The potential for vaccination-driven emergence of a vaccine-
215	resistant strain was demonstrated analytically by Scherer & McLean (2002).
216	The outcome of selection in a vaccinated population will often be a shift in dynamic regime and
217	a substantial increase in the number of cases, relative to a comparable unvaccinated
218	population, because some host individuals will be infected twice, once by the ancestral strain
219	and again by the mutant. If several mutations occur sequentially, each will be likely to spread as
220	its predecessor declines, so that many individuals are infected several times and the total
221	number of cases greatly exceeds that of an unvaccinated population. The effect of vaccination
222	on the total number of cases when there is recurrent mutation at the M-locus is illustrated in
223	Figure 3. In some examples, where no mutation occurs until late in the vaccination program, or

Evolution of virus

Bell

224	fails to spread if it occurs earlier, the resurgence of the epidemic does not occur and
225	vaccination reduces the overall number of infections. In most cases, however, recurrent
226	mutation with $U_{\text{Pot}}\approx 1$ prolongs the epidemic and causes many more cases than would occur in
227	a comparable unvaccinated population, where the number of cases is limited by the number of
228	host individuals, provided that infection confers immunity in recovered individuals. This
229	surprising result follows from the greater selective advantage of strains which carry a mutation
230	at the M-locus in a vaccinated population.
231	Narrow and broad vaccines. A narrow vaccine is highly specific, being efficacious against the
232	ancestral strain of virus but giving little protection against antigenic variants. A broad vaccine is
233	less active against the ancestral strain, but provides some protection against variants, even
234	when complementarity is incomplete. The perfect vaccine would be efficacious against both
235	the ancestral strain and mutational variants, but efficacy and breadth might be incompatible.
236	Suppose that the efficacy E of a vaccine, the probability that it confers immunity to a given
237	strain of virus, declines exponentially with decreasing complementarity C, such that E_{C} = E_{limit}
238	$exp[-k(C_{limit} - C)]$, where E_{limit} is the efficacy of the vaccine when it corresponds perfectly with
239	the M-locus of the strain (C = C_{limit}). A broad vaccine would then have a shallow slope (small k),
240	giving greater protection against similar strains at the expense of giving less protection against
241	matching strains (low E _{limit}). Hence, a broad vaccine might reduce the selective advantage of
242	mutations at the M-locus, and thereby prevent the epidemic from becoming cyclical or
243	perpetual; for example, Fryer & McLean (2011) suggested that broad vaccines against HIV
244	might suppress the emergence of escape mutants. This idea was investigated by manipulating
245	Elimit and k to produce narrow, medium and broad vaccines in populations where mutation at

Evolution of virus

Bell

246	the M-locus (but not the P-locus) was allowed. The outcome showed little effect of vaccine
247	design, but an overwhelming effect of mutation supply. In unvaccinated populations the
248	epidemic was limited, as before (Figure 4). Vaccinated populations behaved in the same way,
249	provided that few mutations occurred, since most mutations fail to spread. Above a certain
250	threshold, however, escape mutations shifted the population into a new regime with multiple
251	infections per host individual and far more cases overall. A narrow vaccine may predispose the
252	population to shift, but the effect is modest at best ($X^2 = 3.0$, df = 1, 0.1 > P > 0.05), whereas the
253	effect of mutation supply is clear.
254	Paradox of vaccination. Simple escape mutations at the M-locus not only prolong the epidemic
255	and increase the number of cases, but may shift the dynamic regime from a limited short-term
256	epidemic to a perennial endemic disease. This outcome is not borne out by empirical data on
257	the effects of vaccination. Most vaccines remain effective for long periods of time, and in many
258	cases (e.g. measles) resistance has never evolved. The rarity of vaccine resistance is particularly
259	striking in contrast with the rapid evolution of resistance to antibiotics (Mishra et al. 2012).
260	
261	This may be a consequence of mutation supply within the host: the immune reaction clears an
262	infection when the pathogen population is still small, whereas antibiotics are usually
263	administered only when the pathogen population has become large enough to cause overt
264	symptoms (Kennedy & Read 2017, 2018; Bell & MacLean 2018). Nevertheless, escape variants
265	have been reported for some vaccines, for example hepatitis B. Even in this case, however,
266	they have failed to eliminate the ancestral strain, perhaps because of a high cost of resistance
267	(Francois et al. 2001). Resistance might often be costly because viral genomes are very

Evolution of virus

268	compact and hence likely to be disrupted by random change. Reid et al. (2019) reviewed a wide
269	range of models designed to predict the consequences of vaccination against an evolving
270	pathogen, most of which referred to a specific vaccine against a particular pathogen. They
271	concluded that: "Overall, the studies of vaccines that have been in use, have trial data, or have
272	existing homologs predicted positive health outcomes despite vaccine resistance." The few
273	exceptions require conditions which are thought to be exceptional, such as high levels of cross-
274	immunity between contemporary strains (e.g. Worby et al. 2017). Hence, real-world studies
275	overwhelmingly predict that vaccination will be beneficial, even in the long term against an
276	evolving pathogen.
277	Vaccine resistance is expected to be rare if the potential mutation supply is usually very low.
278	The rate of mutation per base pair per replication is much higher In RNA viruses than in
279	organisms with a DNA genome, so the requirement that the potential mutation supply be small
280	might seem unlikely. However, the second reason given by Kennedy & Read (2017) for the
281	rarity of vaccine resistance is the extensive redundancy of most vaccines: a variety of antibodies
282	can be produced by the host in response to the presentation of several epitopes on each of
283	several antigens by the pathogen. Consequently, an effective immune response can be
284	mounted against strains similar to, but not identical with, the ancestral strain, leading to the
285	broad cross-reactivity identified by McLean (1995) as a feature of successful vaccines. Most
286	vaccines might therefore tend to be both broad and efficacious, however unlikely such a
287	felicitous combination might seem. Consider a narrow vaccine, which is 100% efficacious
288	against the exactly corresponding sequence at the M-locus of the virus, but otherwise
289	completely inactive, so that a single mutation confers immunity. If the vaccine were somewhat

Evolution of virus

Bell

290	broader, so that it also gave 100% protection against strains that differed at any one of the sites
291	of the M-locus, then a double mutation would be required for immunity. The potential
292	mutation supply now refers to the supply of <i>double</i> mutants, which will be proportional to u^2 .
293	The vaccine now restricts the spread of the virus to a single epidemic, and no shift of dynamic
294	regime occurs (Figure 5). This does not require perfect efficacy. If the vaccine is only 70%
295	efficacious, the number of cases is usually increased only slightly, relative to a perfectly
296	efficacious vaccine. On rare occasions, however, a mutation may occur early in the epidemic
297	and drift to high frequency, such that the mutant lineage is liable to undergo a second mutation
298	before the (rather ineffective) vaccination program has eliminated the virus; it is only in this
299	case that a shift in dynamic regime will occur.
300	Revaccination. If mutation at the M-locus is generating escape mutants, revaccination might
301	halt the spread of a mutant strain, using the most abundant contemporary strain itself as the
302	model for the vaccine. In an unvaccinated population the epidemic will take its normal course,
303	and die out when the virus is no longer able to proliferate. If a single mutation appears before
304	a vaccination program is fully implemented the ancestral strain is eliminated by the vaccine,
305	producing a fall in the number of new cases, but the mutant strain then spreads rapidly. The
306	outcome is an increase in the total number of cases, as previously noted. Revaccination against
307	the most abundant contemporary strain usually palliates this trend, although it is only effective
308	if administered swiftly (Supplementary Figure 3). Revaccination can reduce the number of
309	excess cases if it is administered soon after the previous vaccination program but if it is delayed
310	its effect is less because the mutant strain has already reached high frequency (Figure 3).

Evolution of virus

Bell

311	Recombination. The selection of more highly transmissible variants arising by mutation at the
312	P-locus has only a modest effect on the dynamics of the epidemic, but might be more
313	consequential if they were linked with escape mutants at the M-locus. The probability of
314	stochastic loss of a novel mutation at the M-locus, for example, will be less if it has become
315	linked to a highly transmissible variant caused by mutation at the P-locus. Linkage might arise
316	in two ways: through sequential mutation, or through coinfection leading to intergenic
317	recombination. In principle, recombination is likely to be the more important if coinfection is
318	much more frequent than the rate of mutation per locus. To investigate this possibility,
319	populations with different combinations of mutation and recombination can be set up: neither
320	mutation nor recombination; mutation at the P-locus alone; mutation at the M-locus alone;
321	mutation at both loci without recombination; and mutation at both loci with recombination.
322	The outcome of the experiment is shown in Figure 6. The first three treatments yield results
323	similar to those already described. With neither mutation nor recombination, the epidemic
324	follows a normal course, infecting a substantial proportion of the population before being
325	knocked down by vaccination and then dying out; mutations at the P-locus which increase
326	virulence and transmissibility cause a modest rise in the number of cases, whereas mutations at
327	the M-locus may lead to a new dynamic regime in which the virus evolves to evade the vaccine,
328	many individuals are infected several times and the total number of cases exceeds the
329	population size. When there is mutation at both loci, but no coinfection, linkage must come
330	about as the consequence of a mutation in one locus occurring in a lineage which already bears
331	a mutation at the other. This causes a modest increase in the average number of cases over
332	the course of the epidemic, relative to a population in which mutation occurs only at the M-

Evolution of virus

Bell

333	locus. If coinfection is permitted, linkage m	nay arise either by seq	uential mutation or by
334	recombination. This causes a further increa	ase in the average nur	nber of cases, suggesting an
335	effect of recombination in addition to the e	effect of sequential mu	itation alone. The marginal
336	(additional) effects of mutation and recombination can then be calculated from the five		alculated from the five
337	treatment combinations:		
338	No mutation or recombination	Phe- Imm- Rec-	scaled to 1
339	Mutation at P-locus only	Phe+ Imm- Rec-	1.27
340	Mutation at M-locus only	Phe- Imm+ Rec-	4.38
341	Interaction of P-locus and M-locus	Phe+ Imm+ Rec-	1.23
342	Recombination	Phe+ Imm+ Rec+	1.21
343			
344	These marginal effects largely depend on w	vhether the dynamic re	egime is changed by the
345	treatment rather than a smooth increase ir	n the average number	of cases. The experiment
346	illustrates the overriding qualitative effect	of escape mutations a	t the M-locus and the modest
347	but appreciable quantitative contribution c	of mutations at the P-lo	ocus, either alone or in
348	combination with mutations at the M-locus	s. It is possible that th	e principal effect of
349	recombination, when coinfection is much r	nore frequent than su	ccessful mutation, is to
350	facilitate the transition from a regular limit	ed epidemic to a long-	term endemic infestation.
351	C	onclusions	
352	Virus populations will evolve swiftly when t	there is genetic variation	on for immune characteristics

353 or within-host growth. The maximum quantity of variation is the potential mutation supply,

Evolution of virus

Bell

354	which is the maximum number of mutations in a simple epidemic: U_{Pot} = HuL. This suggests
355	that there is a threshold at about $U_{Pot} = 1$, above which mutations are likely to occur, leading to
356	the evolution of the virus population. The simulations based on an agent-based model broadly
357	support the analytical results of previous theory.
358	Virulence tends to increase when $U_{Pot} > 1$ for the P-locus, and this may be modulated by vaccine
359	design. The total number of cases during the epidemic cannot exceed the number of host
360	individuals, however, and will usually be substantially less. Any increase in morbidity will be
361	limited, especially when a vaccination program has been implemented.
362	Mutation at the M-locus may have a qualitatively different outcome. Escape mutations at the
363	M-locus not only prolong the epidemic and increase the number of cases, but may shift the
364	dynamic regime from a limited short-term epidemic to a perennial endemic disease. Both
365	regimes are examples of evolutionary rescue, because a population that would otherwise
366	become extinct is perpetuated by natural selection through the spread of mutants each of
367	which has a positive rate of increase. Simulations confirm that a shift of dynamic regime is likely
368	to occur when the potential mutation supply $U_{Pot} > 1$. This is because each successful mutation
369	creates its own potential mutation supply and can generate as many new mutations as the
370	ancestral strain. If escape mutations which evade vaccines based on the ancestral virus become
371	established then the epidemic may be prolonged almost indefinitely, unless it can be halted by
372	prompt revaccination. A vaccine which is both broad and efficacious will prevent this shift
373	because only multiply-mutant or recombinant strains will evade the immune response, and it
374	seems likely that most vaccines have this combination of properties.

Evolution of virus

Bell

375	The classic case of a pathogen that has repeatedly evolved vaccine resistance through mutation
376	and recombination is influenza A virus (reviewed by Taubenberger & Kash 2010). SARS-Cov-2 is
377	also a single-stranded RNA virus, and it is possible that escape mutations will occur. The
378	evolution of SARS-Cov-2 up to February 2021 has been reviewed by Rochman et al. (2021).
379	Altmann, Boyton & Beale (2021) have reviewed the evidence (to March 2021) that mutations
380	affecting the spike protein of SARS-Cov-2 cause changes in viral titre or immune recognition or
381	both. All the variants of concern involve several mutations in the spike protein and must have
382	arisen by sequential mutation or recombination or both. Several variants that have spread
383	recently are resistant to plasma from recovered or vaccinated individuals (Wang et al. 2021),
384	and deletions that cause some degree of resistance arise repeatedly in infected patients
385	(McCarthy et al. 2021). The crucial statistic is the frequency of reinfection, which is poorly
386	defined (but not vanishingly small) for SARS-Cov-2 (Boyton & Altmann 2021).
387	Although deterministic processes such as mutation supply and natural selection can be
388	recognised, stochastic processes are also important and may be decisive. All the experiments
389	described in this report show a great deal of scatter, with extreme outliers in some cases and
390	qualitatively different outcomes in others, even when the initial state of the population, the
391	mutation rate and the vaccination schedule are identical. The small size of the host population
392	is responsible for some of this scatter, but the initial fate of a mutant is influenced by the small
393	size (initially a single individual) of the mutant lineage itself, independently of the overall size of
394	the population (see Day et al. 2020, Supplementary Material, equation S8), while the schedule
395	and phenotypic effects of mutations are intrinsically stochastic. In some cases, the effect of a
396	treatment (such as vaccination) or a condition (such as mutation) are quite clear, but in others

Evolution of virus

Bell

397	the outcome is dominated by stochastic processes and the consistent effect of an intervention
398	is difficult to discern. Day et al. (2020) make a similar point on the basis of an analytical
399	mathematical model.
400	More broadly, the dynamics of an epidemic, after the passage of the initial strain, are governed
401	by evolutionary processes involving variation and natural selection. In order to evaluate these
402	processes the most urgent preliminary task is to estimate the potential mutation supply for loci
403	which govern the immune properties and within-host growth of the virus. Practical
404	recommendations which do not include expert guidance on the potential for evolutionary
405	change during the course of an epidemic will be incomplete.
406	
407	Acknowledgments. I am grateful for comments on an earlier version of this article by Austin
408	Burt and Craig MacLean. My research is supported by a Discovery Grant from the Natural

409 Sciences and Engineering Research Board of Canada (Grant RGPIN/6945-2013).

410

Evolution of virus

Bell

41	2
----	---

Figure legends

413	Figure 1. Evolution of virulence in populations with mutation at the P-locus. Plots show the
414	maximum value during the epidemic of mean virulence in naïve (never infected) hosts, for 20
415	replicate populations with identical initial composition but different vaccination status. The
416	upper limit of variation is set at 3x the initial level of virulence. The values of virulence an
417	Figure 2. Dynamics of vaccinated populations with different rates of mutation at the M-locus. E
418	denotes a regular single epidemic; R recurrent cyclical epidemics; Q long-term infestation without clear
419	cyclical structure. The x-axis is the potential mutation supply U_{Pot} per locus, with the vertical line
420	showing $U_{Pot} \approx 1$ as an average for a vaccinated population in which no mutations occur. The horizontal
421	broken line is the population size. The plot shows 6 replicate populations at each of 10 mutation rates;
422	points have been jiggled slightly for clarity.
423	Figure 3. Effect of vaccination and revaccination on the number of cases under recurrent
424	mutation at the M-locus. Treatments for each of 20 replicate populations have identical initial
425	state; different replicates have same parameter values but different initial states. Ranked by
426	number of cases in the vaccinated population. Vaccination beginning 6 weeks after inoculation,
427	in three cohorts spaced by 3 weeks each; revaccination occurs 10 weeks (short lag) or 16 weeks
428	(long lag) after initial vaccination.
429	Figure 4. The effect of vaccine design and mutation supply on the number of cases during an
430	epidemic. The plot shows 20 independent replicate populations for each treatment. The x-axis

431 shows all mutations, whether or not they spread.

Evolution of virus

Bell

432	Figure 5. Effect of a broad efficacious vaccine. Individuals are supposed to be immune only if
433	the vaccine is completely complementary to the strain they are exposed to, so that a single
434	mutation at the I-locus of the virus suffices for infection, or that they are immune if the vaccine
435	differs by no more than one site from the strain they are exposed to, so that a double mutation
436	at the M-locus of the virus is required for infection. The values plotted are the total number of
437	cases during the epidemic, for pairs of populations (20 replicate pairs) with identical initial
438	state. Solid circles refer to a vaccine with 100% efficacy, open triangles with 70% efficacy. The
439	solid line is the line of equality. The dashed line marks the approximate population size of 4000
440	individuals.
441	Figure 6. The effect of mutation and recombination on the total number of infections during an
442	epidemic in a vaccinated population. Mutation either occurs or not at the P-locus (with probability 2 x
443	10^{-4} per bit per replication) and the M-locus (with probability 8 x 10^{-5} per bit per replication), and
444	recombination occurs after coinfection (with probability 0.01 per transmission) or not. Parameters other
445	than the occurrence of mutation or recombination have the same value in all runs. Each of the five
446	treatments has 20 independent realizates, realized in order of increasing number of eaces in each
	treatments has 20 independent replicates, ranked in order of increasing number of cases in each.

447

Evolution of virus

Bell

449

References

- 450 Altmann, D.M., Boyton, R.J. and Beale, R., 2021. Immunity to SARS-CoV-2 variants of
- 451 concern. *Science*, *371*(6534), pp.1103-1104.
- 452 Anderson, R. M. & May, R. M. 1982 Coevolution of hosts and parasites. Parasitology 85, 411-
- 453 426.
- 454 Anderson, R.M. and May, R.M., 1992. *Infectious diseases of humans: dynamics and control*.
- 455 Oxford University Press.
- 456 Bell, G. and MacLean, C., 2018. The search for 'evolution-proof'antibiotics. *Trends in*
- 457 *Microbiology*, *26*(6), pp.471-483.
- 458 Benvenuto, D., Giovanetti, M., Ciccozzi, A., Spoto, S., Angeletti, S. and Ciccozzi, M., 2020. The
- 459 2019-new coronavirus epidemic: evidence for virus evolution. Journal of medical
- 460 *virology*, *92*(4), pp.455-459.
- 461 Boyton, R.J. and Altmann, D.M., 2021. Risk of SARS-CoV-2 reinfection after natural
- 462 infection. *The Lancet*, *397*(10280), pp.1161-1163.
- 463 Brauer, F., 2017. Mathematical epidemiology: Past, present, and future. Infectious Disease
- 464 *Modelling*, *2*(2), pp.113-127.
- 465 Day, T. and Gandon, S., 2007. Applying population-genetic models in theoretical evolutionary
- 466 epidemiology. *Ecology Letters*, *10*(10), pp.876-888.
- 467 Day, T., Gandon, S., Lion, S. and Otto, S.P., 2020. On the evolutionary epidemiology of SARS-
- 468 CoV-2. Current Biology, 30(15), pp.R849-R857.

Evolution of virus

Bell

- 469 Day, T. and Proulx, S.R., 2004. A general theory for the evolutionary dynamics of virulence. The
- 470 *American Naturalist*, *163*(4), pp.E40-E63.
- 471 François, G., Kew, M., Van Damme, P., Mphahlele, M.J. and Meheus, A., 2001. Mutant hepatitis
- 472 B viruses: a matter of academic interest only or a problem with far-reaching
- 473 implications?. *Vaccine*, *19*(28-29), pp.3799-3815.
- 474 Fryer, H.R. and McLean, A.R., 2011. Modelling the spread of HIV immune escape mutants in a
- 475 vaccinated population. *PLoS computational biology*, *7*(12), p.e1002289.
- 476 Gandon, S. and Day, T., 2007. The evolutionary epidemiology of vaccination. Journal of the
- 477 *Royal Society Interface*, *4*(16), pp.803-817.
- 478 Gandon, S., Mackinnon, M. J., Nee, S. & Read, A. F. 2001. Imperfect vaccines and the evolution
- 479 of pathogen virulence. *Nature* **414**, 751–756.
- 480 Gandon, S., Mackinnon, M., Nee, S. & Read, A.F. 2003. Imperfect vaccination: some
- 481 epidemiological and evolutionary consequences. Proceedings of the Royal Society of London B
- 482 270: 1129-1136.
- 483 Gog, J.R. and Grenfell, B.T., 2002. Dynamics and selection of many-strain pathogens.
- 484 *Proceedings of the National Academy of Sciences*, *99*(26), pp.17209-17214.
- 485 Grenfell, B.T., Pybus, O.G., Gog, J.R., Wood, J.L., Daly, J.M., Mumford, J.A. and Holmes, E.C.,
- 486 2004. Unifying the epidemiological and evolutionary dynamics of
- 487 pathogens. *science*, *303*(5656), pp.327-332.

Evolution of virus

Bell

- 488 Kennedy, D.A. and Read, A.F., 2017. Why does drug resistance readily evolve but vaccine
- resistance does not?. *Proceedings of the Royal Society B: Biological Sciences*, 284(1851),

490 p.20162562.

- 491 Kennedy, D.A. and Read, A.F., 2018. Why the evolution of vaccine resistance is less of a concern
- 492 than the evolution of drug resistance. *Proceedings of the National Academy of*
- 493 *Sciences*, *115*(51), pp.12878-12886.
- 494 Lenski, R.E. and May, R.M., 1994. The evolution of virulence in parasites and pathogens:
- 495 reconciliation between two competing hypotheses. Journal of theoretical biology, 169(3),
- 496 pp.253-265.
- 497 May, R.M. and Anderson, R.M., 1983. Epidemiology and genetics in the coevolution of parasites
- 498 and hosts. Proceedings of the Royal society of London. Series B. Biological sciences, 219(1216),

499 pp.281-313.

- 500 McCarthy, K.R., Rennick, L.J., Nambulli, S., Robinson-McCarthy, L.R., Bain, W.G., Haidar, G. and
- 501 Duprex, W.P., 2021. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody
- so2 escape. *Science*, *371*(6534), pp.1139-1142.
- 503 McLean AR. 1995 Vaccination, evolution and changes in the efficacy of vaccines: a theoretical
- 504 framework. Proc. R. Soc. Lond. B 261, 389–393.
- 505 Mishra, R.P., Oviedo-Orta, E., Prachi, P., Rappuoli, R. and Bagnoli, F., 2012. Vaccines and
- antibiotic resistance. *Current opinion in microbiology*, *15*(5), pp.596-602.

Evolution of virus

Bell

- 507 Nelson, M.I. and Holmes, E.C., 2007. The evolution of epidemic influenza. Nature reviews
- 508 *genetics*, *8*(3), pp.196-205.
- 509 Reid, M.C., Peebles, K., Stansfield, S.E., Goodreau, S.M., Abernethy, N., Gottlieb, G.S., Mittler,
- 510 J.E. and Herbeck, J.T., 2019. Models to predict the public health impact of vaccine resistance: A
- 511 systematic review. *Vaccine*, *37*(35), pp.4886-4895.
- Roberts, M.G. and Heesterbeek, J.A.P., 2003. *Mathematical models in epidemiology* (Vol. 215).
 EOLSS.
- 514 Roche, B., Drake, J.M. and Rohani, P., 2011. An Agent-Based Model to study the epidemiological
- and evolutionary dynamics of Influenza viruses. *BMC bioinformatics*, *12*(1), pp.1-10.
- 516 Rochman, N.D., Wolf, Y.I., Faure, G., Mutz, P., Zhang, F. and Koonin, E.V., 2021. Ongoing global
- 517 and regional adaptive evolution of sars-cov-2. *Proceedings of the National Academy of*
- 518 *Sciences*, *118*(29).
- 519 Scherer, A. and McLean, A., 2002. Mathematical models of vaccination. *British Medical*
- 520 Bulletin, 62(1), pp.187-199.
- 521 Taubenberger, J.K. and Kash, J.C., 2010. Influenza virus evolution, host adaptation, and
- pandemic formation. *Cell host & microbe*, 7(6), pp.440-451.
- van Baalen, M. and Sabelis, M.W., 1995. The dynamics of multiple infection and the evolution
- 524 of virulence. *The American Naturalist*, *146*(6), pp.881-910.

Evolution of virus

- 525 Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P.D.
- and Graham, B.S., 2021. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1.
- 527 7. *Nature*, *593*(7857), pp.130-135.
- 528 Worby, C.J., Wallinga, J., Lipsitch, M. and Goldstein, E., 2017. Population effect of influenza
- 529 vaccination under co-circulation of non-vaccine variants and the case for a bivalent A/H3N2
- 530 vaccine component. *Epidemics*, *19*, pp.74-82.



Evolution of virus

Bell

547

548 Figure 2

549



550 551

Evolution of virus

Bell

Figure 3 553

554



556

Evolution of virus

Bell

558 Figure 4

559





Bell

Evolution of virus

588 Figure 6

